Publications by authors named "Barry A Schechter"

Claim this Profile
E
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
Barry A Schechter, Maitee Urbieta, Jason Bacharach, Melissa Toyos, Robert Smyth-Medina

Clin Ophthalmol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.
John Sheppard, Mark Bergmann, Barry A Schechter, Jodi Luchs, Abayomi Ogundele

Clin Ophthalmol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pterygium Surgery Utilizing Limbal Conjunctival Autograft and Subconjunctival Amniotic Membrane Graft in High-Risk Populations.
Alexander Shusko, Barry A Schechter, John A Hovanesian

Clin Ophthalmol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes.
Barry A Schechter, John D Sheppard, Christine M Sanfilippo, Heleen H DeCory, Penny A Asbell

Ophthalmol Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Ranjan Malhotra, Douglas K Devries, Jodi Luchs, Alan Kabat, Barry A Schechter

Cornea· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Damien F Goldberg, Ranjan P Malhotra, Barry A Schechter, Angela Justice, Sidney L Weiss

Ophthalmology· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.
Robert Smyth-Medina, Josh Johnston, Douglas K Devries, April Jasper, Shane R Kannarr, Barry A Schechter

J Ocul Pharmacol Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies.
Barry A Schechter

Clin Ophthalmol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
Joseph Tauber, Barry A Schechter, Jason Bacharach, Melissa M Toyos, Robert Smyth-Medina

Clin Ophthalmol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.
Barry A Schechter, Jai G Parekh, William Trattler

J Ocul Pharmacol Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial survival after Descemet-stripping automated endothelial keratoplasty in eyes with retained anterior chamber intraocular lenses: two-year follow-up.
Salomon Esquenazi, Barry A Schechter, Karina Esquenazi

J Cataract Refract Surg· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bromfenac for the treatment of corneal ulcer pain.
Barry A Schechter, William Trattler

Adv Ther· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of topical cyclosporine for the treatment of ocular rosacea.
Barry A Schechter, Randy S Katz, Lee S Friedman

Adv Ther· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
Barry A Schechter, Aaleya F Koreishi, Carol L Karp, William Feuer

Ophthalmology· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis.
Barry A Schechter

Expert Opin Drug Metab Toxicol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular infections caused by Providencia rettgeri.
Aaleya F Koreishi, Barry A Schechter, Carol L Karp

Ophthalmology· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ketorolac during the induction phase of cyclosporin-A therapy.
Barry A Schechter

J Ocul Pharmacol Ther· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent intraepithelial neoplasia treatment.
Barry A Schechter, Robert S Nagler, Amilia Schrier

Ophthalmology· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal melt after amniotic membrane transplant.
Barry A Schechter, William J Rand, Robert S Nagler, Irving Estrin, Stephen S Arnold

Cornea· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment with 5-Fu.
Barry A Schechter, Robert S Nagler

Ophthalmology· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment with 5-Fu.
Barry A Schechter, Robert S Nagler

Ophthalmology· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of conjunctival papillomata with topical interferon Alfa-2b.
Barry A Schechter, William J Rand, Gabriel E Velazquez, William D Williams, Lewis Starasoler

Am J Ophthalmol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
Barry A Schechter, Amilia Schrier, Robert S Nagler, Edward F Smith, Gabriel E Velasquez

Cornea· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis